stockrowLexicon Pharmaceuticals, Inc. (LXRX) vs OmniAb, Inc. (OABI)
- Lexicon Pharmaceuticals, Inc. LXRX 1.79 +11.18%
- OmniAb, Inc. OABI 5.02 +3.93%
Lexicon Pharmaceuticals, Inc. and OmniAb, Inc. are both Biotechnology companies. Lexicon Pharmaceuticals, Inc. and OmniAb, Inc. are of similar size ($716.4M and $704.5M). OmniAb, Inc. grew revenue faster over the last twelve months: 90.6% against −45.6%. OmniAb, Inc. has the higher net margin (−108.1% vs −161.8%) and the higher return on invested capital (−15.8% vs −109.1%). Across the 17 metrics below, OmniAb, Inc. leads on 13 and Lexicon Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | LXRX | OABI | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.89% | 97.65% | 68.51% |
| Operating margin | (147.42%) | (115.89%) | 0.00% |
| Net margin | (161.80%) | (108.11%) | 0.00% |
| Free cash flow margin | (127.76%) | 5.92% | 0.00% |
| Return on equity | (43.91%) | (16.51%) | (51.96%) |
| Return on assets | (27.84%) | (14.48%) | (46.06%) |
| Return on invested capital | (109.13%) | (15.75%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack